San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor within the weight loss drug marketplace in February soon after revealing promising facts from the mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the